<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36480761</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>S2</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>Atherectomy followed by drug-coated balloon angioplasty for below knee lesions in diabetic patients.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>35</EndPage><MedlinePgn>29-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.22000131</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to compare the long-term outcomes of below the knee revascularization with percutaneous atherectomy followed by drug-coated balloon and revascularization with drug-coated balloon alone for symptomatic diabetic patients with peripheral arterial disease.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between April 2015 and January 2020, total of 128 patients and 228 below the knee procedures were enrolled into this retrospective study. Sixty-five patients were treated with atherectomy followed by drug-coated balloon and 63 patients were treated solely with drug-coated balloon.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Technical success rates were similar in the AT+DCB group and DCB group. Target lesion revascularization (TLR) was found similar in both groups at 6-month follow-up. Clinically, driven repeat endovascular and surgical limb revascularization rates were also significantly lower at 12 and 24 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Combined usage of rotational atherectomy and drug-coated balloons for the treatment of diabetic patients with below-the knee arterial lesions and critical limb ischemia is associated with reduced long-term TLR rates and improved the long-term outcomes.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodoplu</LastName><ForeName>Orhan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Cardiovascular Surgery Clinic, Atasehir Florence Nightingale Hospital, Istanbul.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Er</LastName><ForeName>Zafer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Bozok University Medical Faculty, Yozgat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdinc</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiovascular Surgery Clinic, Izmir Bozyaka Training and Research Hospital, Izmir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozturk</LastName><ForeName>Cuneyd</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Surgery Clinic, Kadikoy Florence Nightingale Hospital, Istanbul. Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Aterectom&#xed;a seguida de angioplastia con bal&#xf3;n recubierto de f&#xe1;rmaco para lesiones debajo de la rodilla en pacientes diab&#xe9;ticos.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000800" MajorTopicYN="Y">Angioplasty, Balloon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017073" MajorTopicYN="N">Atherectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">El objetivo de este estudio fue comparar los resultados a largo plazo de la revascularizaci&#xf3;n por debajo de la rodilla con aterectom&#xed;a percut&#xe1;nea seguida de bal&#xf3;n recubierto de f&#xe1;rmaco y revascularizaci&#xf3;n con bal&#xf3;n recubierto de f&#xe1;rmaco solo en pacientes diab&#xe9;ticos sintom&#xe1;ticos con arteriopat&#xed;a perif&#xe9;rica.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Entre abril de 2015 y enero de 2020, un total de 128 pacientes y 228 procedimientos por debajo de la rodilla se inscribieron en este estudio retrospectivo. Sesenta y cinco pacientes fueron tratados con aterectom&#xed;a seguida de bal&#xf3;n recubierto de f&#xe1;rmaco y 63 pacientes fueron tratados &#xfa;nicamente con bal&#xf3;n recubierto de f&#xe1;rmaco.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Las tasas de &#xe9;xito t&#xe9;cnico fueron similares en el grupo AT+DCB y DCB. La revascularizaci&#xf3;n de la lesi&#xf3;n diana fue similar en ambos grupos a los 6 meses de seguimiento. Las tasas de revascularizaci&#xf3;n endovascular y quir&#xfa;rgica de las extremidades tambi&#xe9;n fueron significativamente m&#xe1;s bajas a los 12 y 24 meses.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">El uso combinado de aterectom&#xed;a rotacional y balones recubiertos de f&#xe1;rmaco para el tratamiento de pacientes diab&#xe9;ticos con lesiones arteriales por debajo de la rodilla e isquemia cr&#xed;tica de las extremidades se asocia con tasas reducidas de revascularizaci&#xf3;n de la lesi&#xf3;n diana a largo plazo y mejores resultados a largo plazo.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aterectom&#xed;a</Keyword><Keyword MajorTopicYN="N">Atherectomy</Keyword><Keyword MajorTopicYN="N">Below the knee peripheral artery disease</Keyword><Keyword MajorTopicYN="N">Chronic limb-threatening ischemia</Keyword><Keyword MajorTopicYN="N">Enfermedad arterial perif&#xe9;rica debajo de la rodilla</Keyword><Keyword MajorTopicYN="N">Isquemia cr&#xf3;nica que amenaza las extremidades</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>8</Day><Hour>15</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36480761</ArticleId><ArticleId IdType="doi">10.24875/CIRU.22000131</ArticleId><ArticleId IdType="pii">j90/S2/29</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24008167</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1579-2021</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion</Title><ISOAbbreviation>Endocrinol Nutr</ISOAbbreviation></Journal><ArticleTitle>[Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: a population study].</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>569</EndPage><MedlinePgn>557-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.endonu.2013.04.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1575-0922(13)00181-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine compliance, metabolic control, complications and healthcare costs of patients treated with metformin started a second antidiabetic drug in patients with type 2 diabetes (T2DM).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Design multicenter observational retrospective. Patients were evaluated &#x2265;30 years (age), treated with metformin and started a second antidiabetic treatment during 2008-2009. There were 4 patient groups (metformin and another antidiabetic): a) dipeptidyl peptidase-4 inhibitors (IDPP4), b) sulfonylureas, c) glitazones and d) insulin.</AbstractText><AbstractText Label="MAIN MEASURES" NlmCategory="METHODS">comorbidity, metabolic control, compliance and complications. Patients were followed for 2 years. The cost model differed direct health costs (primary care / specialist) and indirect (labor productivity).</AbstractText><AbstractText Label="STATISTICAL ANALYSIS" NlmCategory="METHODS">logistic regression models and ANCOVA, p&lt;0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">2067 patients were included (mean age: 66.6 years male: 53.1%). 25.1% started a second treatment with IDPP4; 42.9% sulfonylureas, 14.0% glitazones and 18.0% insulin. At 2 years follow-up, patients treated with IDPP4 showed greater adherence vs. 70.3%. 59.9%, 60.3% and 58.4; better control of 64.3% vs. DM2. 62.6%, 62.8% and 50.5% and a decrease of 13.9% compared to hypoglycaemia 40.4%, 37.6% and 58.9% respectively (p&lt;0.001). The average / unit total costs was &#x20ac;2,321 vs. &#x20ac;2,475, &#x20ac;2,724 and &#x20ac;3,164, respectively, p&lt;0.001. Rates of cardiovascular events and renal failure were 3.7%, 6.4%, 7.6% and 10.2% respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sulfonylureas were the most commonly used drugs. Patients treated with IDPP4 had higher compliance and control of diabetes, with lower rates of hypoglycaemia and healthcare costs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 SEEN. Published by Elsevier Espana. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sicras-Mainar</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n de Planificaci&#xf3;n, Badalona Serveis Assistencials SA, Badalona, Barcelona, Espa&#xf1;a. Electronic address: asicras@bsa.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Font-Ramos</LastName><ForeName>Beatriu</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rold&#xe1;n-Su&#xe1;rez</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Navarro-Artieda</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ib&#xe1;&#xf1;ez-Nolla</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Caracterizaci&#xf3;n y costes asociados al perfil del paciente con diabetes tipo 2 en tratamiento con metformina al que se le a&#xf1;ade un segundo f&#xe1;rmaco antidiab&#xe9;tico oral: estudio de base poblacional.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Endocrinol Nutr</MedlineTA><NlmUniqueID>100886482</NlmUniqueID><ISSNLinking>1575-0922</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular event</Keyword><Keyword MajorTopicYN="N">Compliance</Keyword><Keyword MajorTopicYN="N">Control</Keyword><Keyword MajorTopicYN="N">Costes sanitarios</Keyword><Keyword MajorTopicYN="N">Cumplimiento</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Evento cardiovascular</Keyword><Keyword MajorTopicYN="N">Healthcare costs</Keyword><Keyword MajorTopicYN="N">Hipoglucemias</Keyword><Keyword MajorTopicYN="N">Hypoglycaemias</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24008167</ArticleId><ArticleId IdType="doi">10.1016/j.endonu.2013.04.011</ArticleId><ArticleId IdType="pii">S1575-0922(13)00181-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>